Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life-Reference-Cited by-同舟云学术

Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life

Published:2011 Issue:8 Volume:17 Page:CR442-CR448
ISSN:1234-1010
Container-title:Medical Science Monitor
language:en
Short-container-title:Med Sci Monit

Author:

Panico Annalisa¹,Lupoli Gelsy Arianna¹,Marciello Francesca¹,Lupoli Roberta¹,Cacciapuoti Marianna¹,Martinelli Addolorata¹,Granieri Luciana¹,Iacono Daniela¹,Lupoli Giovanni¹

Affiliation:

1. Department of Molecular and Clinical Endocrinology and Oncology, University “Federico II”, Naples, Italy

Publisher

International Scientific Information, Inc.

Subject

General Medicine

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-09-02

2. Osteoporosis treatment and pain relief: A scoping review;European Journal of Pain;2023-07-05

3. Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: A single-arm, multi-center study;Bone Reports;2023-06

4. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials;BMJ;2023-05-02

5. Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study;Archives of Osteoporosis;2022-07-28